Cash, cash equivalents and marketable securities as of September 30, 2023, totaled $60.5 million, compared to cash, cash equivalents and marketable securities of $98.5 million as of December 31, 2022. Rani expects its cash, cash equivalents and marketable securities to be sufficient to fund its operations through at least the next twelve months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RANI:
- Rani Therapeutics price target lowered to $21 from $26 at Canaccord
- Rani Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
- Rani Therapeutics announces development of RT-101 cancelled, 25% workforce cut
- Rani Therapeutics sees Q3 net loss $17M -$19M
- Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
